Lupin Limited has informed stock exchanges about GST Department inspection and search proceedings initiated at its registered office on February 25, 2026. The pharmaceutical company made the disclosure pursuant to Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015.

GST Department Action Details

The inspection was conducted by the Assistant Commissioner of State Tax, Maharashtra under Section 67 of Maharashtra Goods & Service Tax Act, 2017. The proceedings commenced at 11.50 a.m. (IST) on February 25, 2026, at the company's registered office located at Kalpaturu Inspire, Off W. E. Highway, Santacruz (East), Mumbai.

Company's Response and Cooperation

Lupin has confirmed that it is extending full cooperation with the GST officials and providing all necessary information and documents as requested. The company secretary and compliance officer, Amit Kumar Gupta, signed the disclosure document digitally on February 25, 2026.

Impact Assessment

According to the company's disclosure, the initiation of this inspection and search does not have any impact on Lupin's financials, operations or other activities. The company has characterized this as a routine inspection seeking documentation related to GST compliance and input tax credit claims.

Regulatory Compliance

The disclosure was made to both the National Stock Exchange of India Limited and BSE Limited as required under SEBI Listing Regulations. The company provided detailed information in the prescribed format, including the nature of the action, authority involved, and potential impact on business operations.

Lupin Limited announced a significant regulatory milestone with the U.S. FDA approval of its Abbreviated New Drug Application (ANDA) for Brivaracetam Oral Solution 10 mg/mL. The pharmaceutical company has immediately commenced commercial launch of the product in the United States market following the regulatory clearance.

Product Details and Market Opportunity

The approved Brivaracetam Oral Solution serves as a bioequivalent alternative to UCB Inc.'s Briviact Oral Solution 10 mg/mL. The medication is specifically indicated for the treatment of partial-onset seizures in patients ranging from 1 month of age and older, addressing a critical therapeutic need in pediatric and adult epilepsy care.

Market Potential and Commercial Impact

The market opportunity for this launch appears substantial, with the reference listed drug Briviact recording estimated annual sales of USD 135 million in the U.S. market. This represents a significant revenue opportunity for Lupin as it enters the competitive epilepsy treatment segment with its generic formulation.

Company Profile and Global Presence

Lupin Limited operates as a global pharmaceutical leader headquartered in Mumbai, India, with distribution networks spanning over 100 international markets. The company maintains a diversified portfolio encompassing branded and generic formulations, complex generics, biotechnology products, and active pharmaceutical ingredients.

The company has established strong market positions in India and the United States across multiple therapeutic areas including respiratory, cardiovascular, anti-diabetic, anti-infective, gastrointestinal, central nervous system, and women's health segments. Lupin's commitment to improving patient health outcomes extends through its specialized subsidiaries focusing on diagnostics, digital health solutions, and manufacturing services.